The financial terms of the proposal were kept confidential, but the offer includes the transfer of Arixtra and Fraxiparine
brands (excluding China, India, and Pakistan) to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees.
The group unveiled an agreement earlier this month with Sanofi-Synthelabo to buy injectable drugs Fraxiparine
The group yesterday struck a deal with Sanofi-Synthelabo to buy injectable drugs Fraxiparine
and Arixtra, which have combined annual sales of 343 million euros (pounds 225.
Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine
and its successful clinical use.
In the first quarter of 2013, Arixtra and Fraxiparine
generated sales of [pounds sterling]49 million (up 2% from the year-ago quarter) and [pounds sterling]52 million (down 16% from the year-ago quarter), respectively.
5m deal with Sanofi, which employs 500 people at a factory in Newcastle and 200 at a research and development facility in Alnwick, will see Glaxo acquire injectable drugs Fraxiparine
and Arixtra, which have combined annual sales of u225.
The contract is the supply of medicinal products for the Detention Centre in Bydgoszcz n the following amounts Part 1: positions 989Part 2 Fraxiparine
2850 IU / 0.
5 Fragmin and Fraxiparine
, World Sales ($m), 2008-2024
The contract is for the supply of medicinal products for the Detention Centre in Bydgoszcz in the following amounts Group 1: drugs - 750 itemsGroup 2 Fraxiparine
2850 IU / 0.
Sanofi also developed Fraxiparine
(nadroparin), a LMWH produced by nitrous acid degradation of heparin from porcine intestinal mucosa.
The new Pharmacor report Venous Thromboembolism finds that Sanofi-Aventis's Clexane/Lovenox (enoxaparin), GlaxoSmithKline's Fraxiparine
(nadroparin), and Pfizer's Fragmin (dalteparin) will increase the overall value of the market owing to their increased use in venous thromboembolism prophylaxis following surgery and a continuing switch from the use of unfractionated heparin.
elimination of the income statement contribution of Arixtra, Fraxiparine
and Campto; -- elimination of Aventis Behring, divested at the start of 2004.